India is entering a crucial phase in diabetes and obesity care as the patent for semaglutide expires, opening the door for over 40 pharmaceutical companies to launch cheaper generic versions. This could significantly reduce costs and expand access to a drug that was previously limited due to high prices. While this development offers hope in tackling India’s growing burden of obesity, diabetes, and related diseases, it also raises concerns about whether the healthcare system is ready to handle such rapid expansion.
Past experiences, like the surge of generic dapagliflozin brands, suggest that the market eventually stabilises, with doctors preferring trusted manufacturers. However, semaglutide is more complex—a fragile peptide used in injections and tablets—making it harder to replicate with consistent quality. It also requires strict cold-chain storage, adding further challenges in maintaining effectiveness, especially in remote areas.
With many brands entering the market at once, ensuring quality, safety, and consistency becomes critical. Strong regulatory oversight, continuous monitoring, and strict manufacturing standards will be essential. At the same time, proper education for doctors is necessary, as the drug may reach practitioners with limited experience in using it. Without balanced and independent medical guidance, pharmaceutical promotions could dominate, leading to misuse or overprescribing.
Experts warn that semaglutide should remain a carefully prescribed metabolic therapy, not a casual solution for cosmetic weight loss. Incorrect use without proper evaluation or awareness of side effects—such as nausea, digestive issues, or rare complications—can pose serious risks. Additionally, regulating a crowded market with multiple manufacturers of complex injectable drugs will require robust systems for quality control and safety tracking.
Ultimately, while generic semaglutide presents a major opportunity to improve public health, its success will depend on responsible use, strong regulations, and informed clinical practices. The focus should not just be on increasing availability, but on achieving better health outcomes for patients.
